mTORC1 inhibitor programme II - resTORbio

Drug Profile

mTORC1 inhibitor programme II - resTORbio

Alternative Names: Mechanistic target of rapamycin complex 1 pathway inhibitor programme II - resTORbio; mTOR pathway inhibitor - resTORbio

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer resTORbio
  • Class
  • Mechanism of Action MTORC1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Immunodeficiency disorders

Most Recent Events

  • 24 Mar 2017 Phase-II clinical trials in Immunodeficiency disorders before March 2017
  • 24 Mar 2017 mTORC1 inhibitor licensed to resTORbio
  • 24 Mar 2017 resTORbio plans a phase IIb trial for Immunodeficiency disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top